Overexpression of ANXA3 is an independent prognostic indicator in gastric cancer and its depletion suppresses cell proliferation and tumor growth

Wang, Ke; Li, Jiansheng

doi:10.18632/oncotarget.13493

Cited by 25 publications

(22 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies show that ANXA3 plays an important role in tumor growth and progression. Clinical evidence indicates that ANXA3 could be a potential biomarker of several types of cancers, such as bladder cancer, colon cancer and gastric cancer . It can also serve as an important marker for the invasion, the metastasis and the prognosis of breast cancer…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Cancer‐associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells

Wang

Ren

et al. 2019

Cancer Science

View full text Add to dashboard Cite

Cancer tissues consist of cancer cells, surrounding stromal cells and the extracellular matrix. Cancer‐associated fibroblasts ( CAF ) are one of the key components of stromal cells. CAF have a great impact on the behavior of cancer cells, including proliferation, invasion, metastasis and chemoresistance in many ways. However, the underlying mechanism had not been fully elucidated. In this study, we investigated the role of CAF in cisplatin resistance of lung cancer cells. By using conditioned medium from CAF ( CAF ‐ CM ), we found that CAF decreased the sensitivity of lung cancer cells to cisplatin. RNA sequencing results showed that CAF expressed a higher level of Annexin A3 ( ANXA 3) than normal fibroblasts ( NF ), and CAF ‐ CM incubation increased the ANXA 3 level in lung cancer cells. Overexpression of ANXA 3 in lung cancer cells increased cisplatin resistance and activated c‐jun N‐terminal kinase ( JNK ), whereas knockdown of ANXA 3 increased cisplatin sensitivity. Further study showed that CAF ‐ CM enhanced cisplatin resistance by inhibiting cisplatin‐induced apoptosis, determined by repression of caspase‐3 and caspase‐8, through activation of the ANXA 3/ JNK pathway. Conversely, suppression of JNK activation by specific inhibitor retarded the effect of CAF ‐ CM and ANXA 3 on cisplatin sensitivity. Taken together, our study demonstrated that CAF potentiated chemoresistance of lung cancer cells through a novel ANXA 3/ JNK pathway both in vitro and in vivo, suggesting ANXA 3 could be a potential therapeutic target for the treatment of chemoresistant cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

“…ANXA3 is highly expressed in gastric cancer tissue and cell lines, and overexpression of ANXA3 promoted cell proliferation and colony formation . Zhou et al reported that inhibition of ANXA3 suppressed the proliferation and invasion of breast cancer cells.…”

Section: Discussionmentioning

confidence: 99%

Cancer‐associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells

Wang

Ren

et al. 2019

Cancer Science

View full text Add to dashboard Cite

show abstract

“…ANXA3 has been demonstrated to function either as a tumor suppressor or promoter candidate in different types of cancer. Upregulation of ANXA3 enhances drug resistance and promotes tumor metastasis in breast cancer (47) and promotes tumor growth and predicts poor prognosis in gastric cancer (48), whereas in prostate cancer, ANXA3 protein expression is downregulated, which is associated with the tumor stage and Gleason score (49). In liver cancer, ANXA3 is upregulated and preferentially expressed in cancer stem cells.…”

Section: Discussionmentioning

confidence: 99%

Expression levels and prognostic values of annexins in liver cancer

et al. 2019

View full text Add to dashboard Cite

Annexins are a superfamily of calcium-dependent phospholipid-binding proteins that are implicated in a wide range of biological processes. The annexin superfamily comprises 13 members in humans (ANXAs), the majority of which are frequently dysregulated in cancer. However, the expression patterns and prognostic values of ANXAs in liver cancer are currently largely unknown. The present study aimed to analyze the expression levels of ANXAs and survival data in patients with liver cancer from the Oncomine, GEPIA, Kaplan-Meier plotter and cBioPortal for Cancer Genomics databases. The results demonstrated that ANXA1, A2, A3, A4 and A5 were upregulated, whereas ANXA10 was downregulated in liver cancer compared with normal liver tissues. The expression of ANXA10 was associated with pathological stage. High expression levels of ANXA2 and A5 were significantly associated with poor overall survival (OS) rate whereas ANXA7 and A10 were associated with increased OS. The prognostic values of ANXAs in liver cancer were determined based on sex and clinical stage, which revealed that ANXA2, A5, A7 and A10 were associated with OS in male, but not in female patients. In addition, the potential biological functions of ANXAs were identified by Gene Ontology functional annotation and Kyoto Encyclopedia of Genes Genomes pathway analysis; the results demonstrated that ANXAs may serve a role in liver cancer through the neuroactive ligand-receptor interaction pathway. In conclusion, the results of the present study suggested that ANXA1, A2, A3, A4, A5 and A10 may be potential therapeutic targets for liver cancer treatment, and that ANXA2, A5, A7 and A10 may be potential prognostic biomarkers of liver cancer.

show abstract

“…[42][43][44][45] Notably, a recent study also reported benefits of anti-ANXA3 monoclonal antibodies in a preclinical mouse model of HCC. 45 Although ANXA3 expression in many cancer cells seems to correlate directly with the rate of cellular proliferation, 47,48 the underlying mechanism(s) are undefined. We think that it might be worth investigating a possible role for ANXA3 in extending neutrophil longevitya phenomenon that has been observed during sepsis and is implicated in end-organ damage.…”

Section: Additional Reference Datasets Inform On Anxa3 Restriction Anmentioning

confidence: 99%

Annexin A3 in sepsis: novel perspectives from an exploration of public transcriptome data

et al. 2020

View full text Add to dashboard Cite

According to publicly available transcriptome datasets, the abundance of Annexin A3 (ANXA3) is robustly increased during the course of sepsis; however, no studies have examined the biological significance or clinical relevance of ANXA3 in this pathology. Here we explored this interpretation gap and identified possible directions for future research. Based on reference transcriptome datasets, we found that ANXA3 expression is restricted to neutrophils, is upregulated in vitro after exposure to plasma obtained from septic patients, and is associated with adverse clinical outcomes. Secondly, an increase in ANXA3 transcript abundance was also observed in vivo, in the blood of septic patients in multiple independent studies. ANXA3 is known to mediate calcium-dependent granules-phagosome fusion in support of microbicidal activity in neutrophils. More recent work has also shown that ANXA3 enhances proliferation and survival of tumour cells via a Caspase-3-dependent mechanism. And this same molecule is also known to play a critical role in regulation of apoptotic events in neutrophils. Thus, we posit that during sepsis ANXA3 might either play a beneficial role, by facilitating microbial clearance and resolution of the infection; or a detrimental role, by prolonging neutrophil survival, which is known to contribute to sepsis-mediated organ damage.

show abstract

Overexpression of ANXA3 is an independent prognostic indicator in gastric cancer and its depletion suppresses cell proliferation and tumor growth

Cited by 25 publications

References 30 publications

Cancer‐associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells

Cancer‐associated fibroblasts contribute to cisplatin resistance by modulating ANXA3 in lung cancer cells

Expression levels and prognostic values of annexins in liver cancer

Annexin A3 in sepsis: novel perspectives from an exploration of public transcriptome data

Contact Info

Product

Resources

About